One millionth procedure carried out on Philips Azurion advanced image-guided therapy platform
November 27 2019 - 11:00AM
November 27, 2019
Industry-leading platform combines clinical excellence and
workflow innovation, helping clinicians and hospitals to deliver
outstanding patient care
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced the one millionth procedure on its flagship Azurion
image-guided therapy platform. Since its introduction in February
2017, Azurion has seen rapid adoption in hospitals around the
world, reaching the landmark millionth procedure in just over 2.5
years. The millionth procedure took place at GZA Ziekenhuizen in
Antwerp, Belgium [1].
Image-guided therapy, where treatment is performed through a
small incision and guided by imaging technologies including X-ray
and ultrasound, is increasingly replacing open surgery for the
treatment of many diseases. As the range of diseases that can be
treated with image-guided therapy continues to expand and the
procedures themselves become more efficient, the patient’s
treatment experience continues to improve. They face less trauma,
and as a result their stay in hospital can be dramatically reduced
– often returning home after one night in hospital, and for some
procedures even leaving the hospital on the same day.
“Minimally-invasive image-guided procedures are widely regarded
as the answer to treating more patients, more quickly and at lower
cost,” said Ronald Tabaksblat, General Manager Image Guided Therapy
Systems at Philips. “Working together with clinicians, we use our
comprehensive portfolio of interventional imaging systems, smart
devices, software and services to treat one patient every second
worldwide. The success of Philips Azurion is testament to the
strength of the next-generation platform and our strategy of
continuously innovating procedures to make them more effective and
efficient.”
The procedure was carried out by Dr. Benoit Thomas, a thoracic
and vascular surgeon at GZA Ziekenhuizen. Dr. Thomas’ patient was
treated for a popliteal artery aneurysm – a bulge in the blood
vessel behind the knee which, if left untreated, can potentially
cause blood clots to form. Such a blood clot could cause the loss
of the leg, a stroke or a heart attack. In the hospital’s hybrid
operating room, the patient received a small endovascular stent
graft – a tube-shaped structure inserted into the vessel to
strengthen its walls.
“I’m proud to have treated the millionth patient with the
Azurion, as this system has helped us to improve our workflow and
improved the staff experience,” said Dr. Thomas. “A real benefit of
the Azurion is that we can use previous diagnostic scans and reduce
the amount of radiation for patients and staff. We also see an
improvement in image quality and a decrease in procedure time due
to the setup of the platform and the bedside control-panel.”
Most of today’s image-guided therapy procedures treat
cardiovascular diseases, but its use is expanding into treatment of
diseases in other organs such as the brain, lungs and spine.
Azurion: an industry-leading platform for image-guided
therapyDeveloped in collaboration with leading hospitals
worldwide, Philips Azurion is an innovative image-guided therapy
platform that allows clinicians to easily and confidently perform a
wide range of routine and complex procedures, helping them to
optimize interventional lab performance and provide superior care.
Installed in more than 90 countries, the platform harnesses vital
procedural information from various sources, such as imaging
systems, interventional devices, navigation tools and patient
health records to provide interventional staff with the control and
information they need to perform procedures efficiently.
The latest addition to the image-guided therapy and Azurion
portfolio is the FlexArm, which includes a set of innovations that
makes it easier for the clinician to perform imaging across the
whole patient in both 2D and 3D and helps to reduce repositioning
of the patient, staff and equipment. Philips also recently
introduced the IntraSight interventional applications platform to
seamlessly integrate intravascular imaging and physiology
applications into the interventional lab workflow.
Visit Philips at the RSNA 2019 annual meeting
During the Radiological Society of North America’s (RSNA) 2019
Annual Meeting, December 1-6, in Chicago, U.S., attendees will have
the opportunity to experience Azurion first-hand at the Philips
booth #6730. For more information about Philips’ presence at RSNA,
visit www.philips.com/RSNA and follow @PhilipsLiveFrom for #RSNA19
live updates.
[1] More than one million procedures have been performed on
Philips Azurion based on Philips’ internal case and procedure data.
The one millionth case was estimated based on the same data.
For further information, please contact:
Mark GrovesPhilips Global Press OfficeTel: +31 631 639 916Email:
mark.groves@philips.comTwitter: mark_groves
Fabienne van der FeerPhilips Image Guided TherapyTel: +31 622
698 001Email: fabienne.van.der.feer@philips.comTwitter: FC_Feer
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
enabling better outcomes across the health continuum from healthy
living and prevention, to diagnosis, treatment and home care.
Philips leverages advanced technology and deep clinical and
consumer insights to deliver integrated solutions. Headquartered in
the Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2018
sales of EUR 18.1 billion and employs approximately 80,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
- Philips_Azurion_with_FlexArm
- Philips_Azurion_procedure_GZA_Ziekenhuizen
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Sep 2023 to Sep 2024